Recursion Pharmaceuticals, Inc. $RXRX Shares Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 537.3% in the 4th quarter, HoldingsChannel reports. The firm owned 818,316 shares of the company’s stock after purchasing an additional 689,903 shares during the quarter. Hsbc Holdings PLC’s holdings in Recursion Pharmaceuticals were worth $3,367,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. NewEdge Advisors LLC boosted its position in Recursion Pharmaceuticals by 28.1% in the second quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock valued at $56,000 after buying an additional 2,428 shares during the last quarter. Equitable Holdings Inc. lifted its stake in Recursion Pharmaceuticals by 7.1% during the 3rd quarter. Equitable Holdings Inc. now owns 39,400 shares of the company’s stock valued at $192,000 after acquiring an additional 2,600 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in Recursion Pharmaceuticals by 1.2% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 232,370 shares of the company’s stock valued at $954,000 after acquiring an additional 2,753 shares during the period. Daiwa Securities Group Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 29.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,706 shares of the company’s stock valued at $64,000 after acquiring an additional 2,883 shares during the last quarter. Finally, Ascent Wealth Partners LLC boosted its holdings in shares of Recursion Pharmaceuticals by 15.3% in the 4th quarter. Ascent Wealth Partners LLC now owns 25,107 shares of the company’s stock valued at $103,000 after acquiring an additional 3,336 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Wall Street Zen cut shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. JPMorgan Chase & Co. cut their price target on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Morgan Stanley lifted their price objective on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.10.

Recursion Pharmaceuticals Trading Down 5.3%

RXRX stock opened at $3.56 on Friday. The company’s 50-day simple moving average is $3.34 and its 200-day simple moving average is $3.64. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals, Inc. has a 52-week low of $2.77 and a 52-week high of $7.18. The firm has a market cap of $1.89 billion, a P/E ratio of -2.97 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.08. The firm had revenue of $6.47 million during the quarter, compared to analyst estimates of $15.78 million. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.Recursion Pharmaceuticals’s revenue for the quarter was down 56.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.50) EPS. As a group, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 23,588 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $3.58, for a total value of $84,445.04. Following the sale, the chief executive officer directly owned 2,175,796 shares of the company’s stock, valued at approximately $7,789,349.68. This trade represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total value of $158,400.00. Following the completion of the sale, the director owned 6,218,287 shares of the company’s stock, valued at $24,624,416.52. This trade represents a 0.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 131,937 shares of company stock worth $486,974. 6.65% of the stock is owned by corporate insiders.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.